Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus
Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CR...
Gespeichert in:
| Veröffentlicht in: | Clinical colorectal cancer 2014-09, Vol.13 (3), p.145-155 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 155 |
|---|---|
| container_issue | 3 |
| container_start_page | 145 |
| container_title | Clinical colorectal cancer |
| container_volume | 13 |
| creator | Cheng, Ann-Lii Li, Jin Vaid, Ashok K Ma, Brigette Buig Yue Teh, Catherine Ahn, Joong B Bello, Maximino Charoentum, Chaiyut Chen, Li-Tzong de Lima Lopes, Gilberto Ho, Gwo F Kong, Hwai L Lam, Ka O Liu, Tian S Park, Young S Sriuranpong, Virote Sudoyo, Aru W Wang, Jaw-Yuan Zhang, Jun Zhang, Su Z Ciardiello, Fortunato Köhne, Clause-Henning Shaw, Michael Kim, Tae Won |
| description | Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for K RAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available. |
| doi_str_mv | 10.1016/j.clcc.2014.06.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561973301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1533002814000656</els_id><sourcerecordid>1561973301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-e18405557bc26ca6e1bbaf3085b6a5b0083f4849c6d101314f98bf22b6705c53</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0E6mPoH2CBsmSTcP1MghDSaNSWSkUs6I6F5Tg3kgePPdgJUv89TqewYMHK17rnXOl8h5A3FBoKVL3fN9Zb2zCgogHVAIgX5IL2vKtBteJlmSXnNQDrzsllzvsyKU7pGTlnkkEPPb8g37ejOc5mdjFUcaruwowpPH2Nr24XN6J3AXM1xVR9wdnkVWurXfQxoZ2LaGeCxfSh2oZqm50JZRcyhrzk1-TVZHzGq-d3Qx5urh92n-v7r7d3u-19bUXbzjXSToCUsh0sU9YopMNgJg6dHJSRA0DHJ9GJ3qqxxOZUTH03TIwNqgVpJd-Qd6ezxxR_LphnfXDZovcmYFyyplLRvuW8eDeEnaQ2xZwTTvqY3MGkR01Br0z1Xq9M9cpUg9KFaTG9fb6_DAcc_1r-QCyCjycBlpC_HCadrcNCZXQrIz1G9__7n_6x28LcWeN_4CPmfVxKI77k0Jlp0N_WVtdSqQAAJRX_DeLjm-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561973301</pqid></control><display><type>article</type><title>Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Cheng, Ann-Lii ; Li, Jin ; Vaid, Ashok K ; Ma, Brigette Buig Yue ; Teh, Catherine ; Ahn, Joong B ; Bello, Maximino ; Charoentum, Chaiyut ; Chen, Li-Tzong ; de Lima Lopes, Gilberto ; Ho, Gwo F ; Kong, Hwai L ; Lam, Ka O ; Liu, Tian S ; Park, Young S ; Sriuranpong, Virote ; Sudoyo, Aru W ; Wang, Jaw-Yuan ; Zhang, Jun ; Zhang, Su Z ; Ciardiello, Fortunato ; Köhne, Clause-Henning ; Shaw, Michael ; Kim, Tae Won</creator><creatorcontrib>Cheng, Ann-Lii ; Li, Jin ; Vaid, Ashok K ; Ma, Brigette Buig Yue ; Teh, Catherine ; Ahn, Joong B ; Bello, Maximino ; Charoentum, Chaiyut ; Chen, Li-Tzong ; de Lima Lopes, Gilberto ; Ho, Gwo F ; Kong, Hwai L ; Lam, Ka O ; Liu, Tian S ; Park, Young S ; Sriuranpong, Virote ; Sudoyo, Aru W ; Wang, Jaw-Yuan ; Zhang, Jun ; Zhang, Su Z ; Ciardiello, Fortunato ; Köhne, Clause-Henning ; Shaw, Michael ; Kim, Tae Won</creatorcontrib><description>Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for K RAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.</description><identifier>ISSN: 1533-0028</identifier><identifier>EISSN: 1938-0674</identifier><identifier>DOI: 10.1016/j.clcc.2014.06.004</identifier><identifier>PMID: 25209093</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asia ; Bevacizumab ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; Cetuximab ; Chemotherapy ; Colonic Neoplasms - genetics ; Colonic Neoplasms - pathology ; Colonic Neoplasms - therapy ; Combined Modality Therapy ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Drug Combinations ; Epidermal growth factor receptor (EGFR)-specific monoclonal antibody ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Fluorouracil - therapeutic use ; Gastroenterology and Hepatology ; Guideline Adherence ; Hematology, Oncology and Palliative Medicine ; Humans ; KRAS ; Leucovorin - administration & dosage ; Liver Neoplasms - genetics ; Liver Neoplasms - secondary ; Liver Neoplasms - therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - secondary ; Lung Neoplasms - therapy ; Magnetic Resonance Imaging ; Metastasectomy ; Neoplasm Staging ; Organoplatinum Compounds - administration & dosage ; Oxonic Acid - administration & dosage ; Practice Guidelines as Topic ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Rectal Neoplasms - genetics ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Targeted therapy ; Tegafur - administration & dosage ; Tomography, X-Ray Computed]]></subject><ispartof>Clinical colorectal cancer, 2014-09, Vol.13 (3), p.145-155</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-e18405557bc26ca6e1bbaf3085b6a5b0083f4849c6d101314f98bf22b6705c53</citedby><cites>FETCH-LOGICAL-c477t-e18405557bc26ca6e1bbaf3085b6a5b0083f4849c6d101314f98bf22b6705c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clcc.2014.06.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3548,23929,23930,25139,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25209093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Ann-Lii</creatorcontrib><creatorcontrib>Li, Jin</creatorcontrib><creatorcontrib>Vaid, Ashok K</creatorcontrib><creatorcontrib>Ma, Brigette Buig Yue</creatorcontrib><creatorcontrib>Teh, Catherine</creatorcontrib><creatorcontrib>Ahn, Joong B</creatorcontrib><creatorcontrib>Bello, Maximino</creatorcontrib><creatorcontrib>Charoentum, Chaiyut</creatorcontrib><creatorcontrib>Chen, Li-Tzong</creatorcontrib><creatorcontrib>de Lima Lopes, Gilberto</creatorcontrib><creatorcontrib>Ho, Gwo F</creatorcontrib><creatorcontrib>Kong, Hwai L</creatorcontrib><creatorcontrib>Lam, Ka O</creatorcontrib><creatorcontrib>Liu, Tian S</creatorcontrib><creatorcontrib>Park, Young S</creatorcontrib><creatorcontrib>Sriuranpong, Virote</creatorcontrib><creatorcontrib>Sudoyo, Aru W</creatorcontrib><creatorcontrib>Wang, Jaw-Yuan</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Zhang, Su Z</creatorcontrib><creatorcontrib>Ciardiello, Fortunato</creatorcontrib><creatorcontrib>Köhne, Clause-Henning</creatorcontrib><creatorcontrib>Shaw, Michael</creatorcontrib><creatorcontrib>Kim, Tae Won</creatorcontrib><title>Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus</title><title>Clinical colorectal cancer</title><addtitle>Clin Colorectal Cancer</addtitle><description>Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for K RAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.</description><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asia</subject><subject>Bevacizumab</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Cetuximab</subject><subject>Chemotherapy</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - therapy</subject><subject>Combined Modality Therapy</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Drug Combinations</subject><subject>Epidermal growth factor receptor (EGFR)-specific monoclonal antibody</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastroenterology and Hepatology</subject><subject>Guideline Adherence</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>KRAS</subject><subject>Leucovorin - administration & dosage</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - therapy</subject><subject>Magnetic Resonance Imaging</subject><subject>Metastasectomy</subject><subject>Neoplasm Staging</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Oxonic Acid - administration & dosage</subject><subject>Practice Guidelines as Topic</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Rectal Neoplasms - genetics</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>Targeted therapy</subject><subject>Tegafur - administration & dosage</subject><subject>Tomography, X-Ray Computed</subject><issn>1533-0028</issn><issn>1938-0674</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAUhS0E6mPoH2CBsmSTcP1MghDSaNSWSkUs6I6F5Tg3kgePPdgJUv89TqewYMHK17rnXOl8h5A3FBoKVL3fN9Zb2zCgogHVAIgX5IL2vKtBteJlmSXnNQDrzsllzvsyKU7pGTlnkkEPPb8g37ejOc5mdjFUcaruwowpPH2Nr24XN6J3AXM1xVR9wdnkVWurXfQxoZ2LaGeCxfSh2oZqm50JZRcyhrzk1-TVZHzGq-d3Qx5urh92n-v7r7d3u-19bUXbzjXSToCUsh0sU9YopMNgJg6dHJSRA0DHJ9GJ3qqxxOZUTH03TIwNqgVpJd-Qd6ezxxR_LphnfXDZovcmYFyyplLRvuW8eDeEnaQ2xZwTTvqY3MGkR01Br0z1Xq9M9cpUg9KFaTG9fb6_DAcc_1r-QCyCjycBlpC_HCadrcNCZXQrIz1G9__7n_6x28LcWeN_4CPmfVxKI77k0Jlp0N_WVtdSqQAAJRX_DeLjm-w</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Cheng, Ann-Lii</creator><creator>Li, Jin</creator><creator>Vaid, Ashok K</creator><creator>Ma, Brigette Buig Yue</creator><creator>Teh, Catherine</creator><creator>Ahn, Joong B</creator><creator>Bello, Maximino</creator><creator>Charoentum, Chaiyut</creator><creator>Chen, Li-Tzong</creator><creator>de Lima Lopes, Gilberto</creator><creator>Ho, Gwo F</creator><creator>Kong, Hwai L</creator><creator>Lam, Ka O</creator><creator>Liu, Tian S</creator><creator>Park, Young S</creator><creator>Sriuranpong, Virote</creator><creator>Sudoyo, Aru W</creator><creator>Wang, Jaw-Yuan</creator><creator>Zhang, Jun</creator><creator>Zhang, Su Z</creator><creator>Ciardiello, Fortunato</creator><creator>Köhne, Clause-Henning</creator><creator>Shaw, Michael</creator><creator>Kim, Tae Won</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus</title><author>Cheng, Ann-Lii ; Li, Jin ; Vaid, Ashok K ; Ma, Brigette Buig Yue ; Teh, Catherine ; Ahn, Joong B ; Bello, Maximino ; Charoentum, Chaiyut ; Chen, Li-Tzong ; de Lima Lopes, Gilberto ; Ho, Gwo F ; Kong, Hwai L ; Lam, Ka O ; Liu, Tian S ; Park, Young S ; Sriuranpong, Virote ; Sudoyo, Aru W ; Wang, Jaw-Yuan ; Zhang, Jun ; Zhang, Su Z ; Ciardiello, Fortunato ; Köhne, Clause-Henning ; Shaw, Michael ; Kim, Tae Won</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-e18405557bc26ca6e1bbaf3085b6a5b0083f4849c6d101314f98bf22b6705c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asia</topic><topic>Bevacizumab</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Cetuximab</topic><topic>Chemotherapy</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - therapy</topic><topic>Combined Modality Therapy</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Drug Combinations</topic><topic>Epidermal growth factor receptor (EGFR)-specific monoclonal antibody</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastroenterology and Hepatology</topic><topic>Guideline Adherence</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>KRAS</topic><topic>Leucovorin - administration & dosage</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - therapy</topic><topic>Magnetic Resonance Imaging</topic><topic>Metastasectomy</topic><topic>Neoplasm Staging</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Oxonic Acid - administration & dosage</topic><topic>Practice Guidelines as Topic</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Rectal Neoplasms - genetics</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>Targeted therapy</topic><topic>Tegafur - administration & dosage</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Ann-Lii</creatorcontrib><creatorcontrib>Li, Jin</creatorcontrib><creatorcontrib>Vaid, Ashok K</creatorcontrib><creatorcontrib>Ma, Brigette Buig Yue</creatorcontrib><creatorcontrib>Teh, Catherine</creatorcontrib><creatorcontrib>Ahn, Joong B</creatorcontrib><creatorcontrib>Bello, Maximino</creatorcontrib><creatorcontrib>Charoentum, Chaiyut</creatorcontrib><creatorcontrib>Chen, Li-Tzong</creatorcontrib><creatorcontrib>de Lima Lopes, Gilberto</creatorcontrib><creatorcontrib>Ho, Gwo F</creatorcontrib><creatorcontrib>Kong, Hwai L</creatorcontrib><creatorcontrib>Lam, Ka O</creatorcontrib><creatorcontrib>Liu, Tian S</creatorcontrib><creatorcontrib>Park, Young S</creatorcontrib><creatorcontrib>Sriuranpong, Virote</creatorcontrib><creatorcontrib>Sudoyo, Aru W</creatorcontrib><creatorcontrib>Wang, Jaw-Yuan</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Zhang, Su Z</creatorcontrib><creatorcontrib>Ciardiello, Fortunato</creatorcontrib><creatorcontrib>Köhne, Clause-Henning</creatorcontrib><creatorcontrib>Shaw, Michael</creatorcontrib><creatorcontrib>Kim, Tae Won</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical colorectal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Ann-Lii</au><au>Li, Jin</au><au>Vaid, Ashok K</au><au>Ma, Brigette Buig Yue</au><au>Teh, Catherine</au><au>Ahn, Joong B</au><au>Bello, Maximino</au><au>Charoentum, Chaiyut</au><au>Chen, Li-Tzong</au><au>de Lima Lopes, Gilberto</au><au>Ho, Gwo F</au><au>Kong, Hwai L</au><au>Lam, Ka O</au><au>Liu, Tian S</au><au>Park, Young S</au><au>Sriuranpong, Virote</au><au>Sudoyo, Aru W</au><au>Wang, Jaw-Yuan</au><au>Zhang, Jun</au><au>Zhang, Su Z</au><au>Ciardiello, Fortunato</au><au>Köhne, Clause-Henning</au><au>Shaw, Michael</au><au>Kim, Tae Won</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus</atitle><jtitle>Clinical colorectal cancer</jtitle><addtitle>Clin Colorectal Cancer</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>13</volume><issue>3</issue><spage>145</spage><epage>155</epage><pages>145-155</pages><issn>1533-0028</issn><eissn>1938-0674</eissn><abstract>Abstract Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional ‘real-world’ experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for K RAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25209093</pmid><doi>10.1016/j.clcc.2014.06.004</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1533-0028 |
| ispartof | Clinical colorectal cancer, 2014-09, Vol.13 (3), p.145-155 |
| issn | 1533-0028 1938-0674 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1561973301 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asia Bevacizumab Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cetuximab Chemotherapy Colonic Neoplasms - genetics Colonic Neoplasms - pathology Colonic Neoplasms - therapy Combined Modality Therapy Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Combinations Epidermal growth factor receptor (EGFR)-specific monoclonal antibody Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Gastroenterology and Hepatology Guideline Adherence Hematology, Oncology and Palliative Medicine Humans KRAS Leucovorin - administration & dosage Liver Neoplasms - genetics Liver Neoplasms - secondary Liver Neoplasms - therapy Lung Neoplasms - genetics Lung Neoplasms - secondary Lung Neoplasms - therapy Magnetic Resonance Imaging Metastasectomy Neoplasm Staging Organoplatinum Compounds - administration & dosage Oxonic Acid - administration & dosage Practice Guidelines as Topic Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Receptor, Epidermal Growth Factor - antagonists & inhibitors Rectal Neoplasms - genetics Rectal Neoplasms - pathology Rectal Neoplasms - therapy Targeted therapy Tegafur - administration & dosage Tomography, X-Ray Computed |
| title | Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A17%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adaptation%20of%20International%20Guidelines%20for%20Metastatic%20Colorectal%20Cancer:%20An%20Asian%20Consensus&rft.jtitle=Clinical%20colorectal%20cancer&rft.au=Cheng,%20Ann-Lii&rft.date=2014-09-01&rft.volume=13&rft.issue=3&rft.spage=145&rft.epage=155&rft.pages=145-155&rft.issn=1533-0028&rft.eissn=1938-0674&rft_id=info:doi/10.1016/j.clcc.2014.06.004&rft_dat=%3Cproquest_cross%3E1561973301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1561973301&rft_id=info:pmid/25209093&rft_els_id=S1533002814000656&rfr_iscdi=true |